BioInvent has biggest war chest on the block

26 January 2022

Swedish immuno-oncology firm BioInvent (OMXS: BINV), the first company to discover two innovative new cancer antibody targets, is fully funded to develop antibodies across five clinical projects over the coming three to four years.

Being a biotech company with a large war chest makes this an investment for biotech and more risk-averse investors alike, according to Swedish investment bank Redeye analyst Richard Ramanius.

During 2020-21, BioInvent opportunistically raised around 1.5 billion Swedish kronor ($163 million), which will finance its broad pipeline of five clinical projects until 2025. Investors do not have to worry about share issues in the near term.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK